Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.
포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.
터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
– Die Ergebnisse der Phase-2-Studie L-MIND wurden auf der Jahrestagung der American Association for Cancer Research 2023 in einer...
- Results from the Phase 2 L-MIND study were highlighted as a late-breaking oral presentation at the American Association for Cancer Research...
– Topline data from the Phase 3 MANIFEST-2 study expected in early 2024 – Monjuvi® U.S. net product sales of US$ 25.3 million (€ 24.7 million...
– Monjuvi® U.S. net product sales of US$ 22.2 million (€ 21.9 million) for the third quarter of 2022 – Presentation of preliminary results from...
– Monjuvi® U.S. net product sales of US$ 23.3 million (€ 21.7 million) for the second quarter 2022, a 25% Q-Q growth and 29% Y-Y growth –...
I-Mab Partner MorphoSys Announces New License Agreements for Felzartamab and TJ210 PR Newswire SHANGHAI and...
Human Immunology Biosciences (HIBio) is a biotechnology company focused on developing precision medicines for autoimmune and inflammatory...
New translational data suggests potential disease-modifying effects following treatment with pelabresib of both first-line and...
Efficacy and safety data from the ongoing Phase 2 MANIFEST study of pelabresib in myelofibrosis will be featured during an oral presentation at...
– Monjuvi® U.S. net product sales of US$ 18.7 million (€ 16.6 million) for the first quarter 2022, a 21% year-over-year growth – NCCN® updated...
– Monjuvi® U.S. net product sales of US$ 23.6 million (€ 20.5 million) for the fourth quarter and US$ 79.1 million (€ 66.9 million) for the full...
RE-MIND2 compared patient outcomes from pivotal L-MIND study with matched patient populations treated with NCCN/ESMO recommended therapies...
- La décision de la Commission européenne est basée sur les données de l’étude L-MIND évaluant Minjuvi en association avec le lénalidomide comme...
- Entscheidung der Kommission basiert auf Daten aus der Studie L-MIND zur Prüfung von Minjuvi in Kombination mit Lenalidomid als Behandlung von...
귀하가 조회한 주식이 이 박스에 나타나며 쉽게 최근 시세로 돌아갈 수 있습니다.
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관